MND PROMOTER CHIMERIC ANTIGEN RECEPTORSThe invention provides vector compositions for delivering improved adoptive T cell therapies.MORGAN RichardFRIEDMAN KevinRYU Byoung
An evaluation of a SVA retrotransposon in the FUS promoter as a transcriptional regulator and its association to ALS. PLoS One. 2014;9(6), e90833. doi:10.1371/journal.pone.0090833. eCollection 2014. Article PubMed Central PubMed Google Scholar Cooper-Knock J, Walsh MJ, Higginbottom A, ...
方法:构建c-MYC启动子的荧光报告质粒及其突变体,经过序列测定后,转染HEK293细胞24h后,以终浓度为0μmol/L,0.1μmol/L,1.0μmol/L,10μmol/L,100μmol/L的TETA处理,测定其启动子的转录活性,计算TETA对其转录活性抑制率。 结果:成功构建c-MYC启动子荧光报告质粒PGL3-Basic/c-MYC NHE III1 promoter及其突变体...
United States Patent US10774343 Note: If you have problems viewing the PDF, please make sure you have the latest version ofAdobe Acrobat. Back to full text
MND PROMOTER CHIMERIC ANTIGEN RECEPTORSThe invention provides vector compositions for delivering improved adoptive T cell therapies.MORGAN, RICHARDFRIEDMAN, KEVINRYU, BYOUNG
MND PROMOTER CHIMERIC ANTIGEN RECEPTORSThe invention provides vector compositions for delivering improved adoptive T cell therapies.MORGAN, RICHARDFRIEDMAN, KEVINRYU, BYOUNG
Luciferase reporter and ChIP assays found that E2F1 activated MND1 transcription by binding to its promoter in a feedback manner. Conclusions MND1, KLF6, and E2F1 form a positive feedback loop to regulate cell cycle and confer DDP resistance in LUAD. MND1 is crucial for malignant progression ...
(E2F1)from KLF6-induced transcriptional repression.Luciferase reporter and ChIP assays found that E2F1 activated MND1 transcription by binding to its promoter in a feedback manner.Conclusions:MND1,KLF6,and E2F1 form a positive feedback loop to regulate cell cycle and confer DDP resistance in LUAD...
MND PROMOTER CHIMERIC ANTIGEN RECEPTORSThe invention provides vector compositions for delivering improved adoptive T cell therapies.MORGAN, RICHARDFRIEDMAN, KEVINRYU, BYOUNG
MND PROMOTER CHIMERIC ANTIGEN RECEPTORSThe invention provides vector compositions for delivering improved adoptive T cell therapies.MORGAN, RICHARDFRIEDMAN, KEVINRYU, BYOUNG